- Supported exchanges /
- F /
- EU6.F
PDS Biotechnology Corp (EU6 F) stock market data APIs
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.
PDS Biotechnology Corp Financial Data Overview
| 2.848 | |
| 2.848 | |
| - | |
| 2.848 | |
| 2.848 | |
| 2.336-6.08 | |
| 111 M | |
| 36 820 K | |
| 0 | |
| -0.35 | |
| 1.897 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PDS Biotechnology Corp Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -39 650 236
- Earnings Per Share -1.13
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get PDS Biotechnology Corp Earnings via APIs
- Latest Release 2023-11-14
- EPS/Forecast -0.39
Get PDS Biotechnology Corp End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
